Sign in
4

Changes in Ownership

Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000121

Options or other derivatives

  • Chief Executive Officer acquired 965,435 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
BLATT LAWRENCE Chief Executive Officer 2024-03-01 Grant or award · Stock Option (Right to Buy) +965,435 965,435 D: show line 1 in the form
Loading xslF345X05/form4.xml…